Sanofi extends Aventis offer
Aventis U.S. shareholders have until June 30 to exchange shares for Sanofi stock; the offer was previously set to close May 28. Sale of Sanofi's thrombosis franchise Arixtra and Fraxiparine to GlaxoSmithKline was approved by the European Commission May 26. Companies are awaiting final clearance of merger and product sale by Federal Trade Commission. Sanofi and Aventis agreed to $65 bil. merger April 25 (1"The Pink Sheet" May 3, 2004, p. 3)...
You may also be interested in...
Sanofi's winning bid for Aventis includes an additional $8 bil. in cash, nominal joint control of the merged company, and an acknowledgment of Aventis' Franco-German heritage
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.